Dashboard
Manage Tickers

AMGN AMGEN INC

Nasdaq amgen.com


$ 320.60 $ 4.61 (1.46 %)    

Friday, 07-Nov-2025 18:38:21 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 612.14 $ 1.56 (0.26 %)
DIA $ 470.45 $ 1.64 (0.35 %)
SPY $ 672.31 $ 2.95 (0.44 %)
TLT $ 89.45 $ -0.19 (-0.21 %)
GLD $ 367.77 $ 0.35 (0.1 %)
$ 320.2
$ 316.08
$ 315.75 x 1
$ 322.00 x 50
$ 314.00 - $ 321.42
$ 247.06 - $ 330.26
2,665,384
na
172.42B
$ 0.46
$ 24.61
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 08-05-2025 06-30-2025 10-Q
3 05-01-2025 03-31-2025 10-Q
4 02-14-2025 12-31-2024 10-K
5 10-30-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 02-14-2024 12-31-2023 10-K
9 10-31-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 04-28-2023 03-31-2023 10-Q
12 02-09-2023 12-31-2022 10-K
13 11-04-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 04-28-2022 03-31-2022 10-Q
16 02-16-2022 12-31-2021 10-K
17 11-03-2021 09-30-2021 10-Q
18 08-03-2021 06-30-2021 10-Q
19 04-28-2021 03-31-2021 10-Q
20 02-09-2021 12-31-2020 10-K
21 10-29-2020 09-30-2020 10-Q
22 07-29-2020 06-30-2020 10-Q
23 05-01-2020 03-31-2020 10-Q
24 02-12-2020 12-31-2019 10-K
25 10-30-2019 09-30-2019 10-Q
26 07-31-2019 06-30-2019 10-Q
27 05-01-2019 03-31-2019 10-Q
28 02-13-2019 12-31-2018 10-K
29 10-31-2018 09-30-2018 10-Q
30 07-27-2018 06-30-2018 10-Q
31 04-25-2018 03-31-2018 10-Q
32 02-13-2018 12-31-2017 10-K
33 10-26-2017 09-30-2017 10-Q
34 07-26-2017 06-30-2017 10-Q
35 04-27-2017 03-31-2017 10-Q
36 02-14-2017 12-31-2016 10-K
37 10-28-2016 09-30-2016 10-Q
38 07-29-2016 06-30-2016 10-Q
39 05-02-2016 03-31-2016 10-Q
40 02-16-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

amgens-repatha-cuts-risk-of-first-major-adverse-cardiovascular-events-by-25-heart-attack-risk-by-36-in-phase-3-vesalius-cv-trial
Amgen's Repatha Cuts Risk Of First Major A...
11/08/2025 15:22:27

Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (e...

watching-amgen-hearing-investor-business-daily-swingtrader-buys-stock
Watching Amgen; Hearing Investor Business ...
11/07/2025 18:57:23

cantor-fitzgerald-maintains-neutral-on-amgen-raises-price-target-to-315
Cantor Fitzgerald Maintains Neutral on Amg...
11/06/2025 15:06:36

Cantor Fitzgerald analyst Carter Gould maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $305 to...

stocks-rebound-eli-lilly-jumps-to-14-month-highs-whats-moving-markets-wednesday
Stocks Rebound, Eli Lilly Jumps To 14-Mont...
11/05/2025 18:23:55

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid soli...

morgan-stanley-maintains-equal-weight-on-amgen-lowers-price-target-to-329
Morgan Stanley Maintains Equal-Weight on A...
11/05/2025 17:59:53

Morgan Stanley analyst Terence Flynn maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and lowers the price target from $333...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
11/05/2025 17:35:20

wells-fargo-maintains-overweight-on-amgen-raises-price-target-to-300
Wells Fargo Maintains Overweight on Amgen,...
11/05/2025 15:00:26

Wells Fargo analyst Mohit Bansal maintains Amgen (NASDAQ:AMGN) with a Overweight and raises the price target from $280 to $300.

amgen-raises-fy2025-sales-guidance-from-35000b-36000b-to-35800b-36600b-vs-35659b-est
Amgen Raises FY2025 Sales Guidance from $3...
11/04/2025 21:36:15

2025 GuidanceFor the full year 2025, the Company expects:Total revenues in the range of $35.8 billion to $36.6 billion.On a GAA...

amgen-raises-fy2025-gaap-eps-guidance-from-1097-1211-to-1376-1460-vs-1136-est
Amgen Raises FY2025 GAAP EPS Guidance from...
11/04/2025 21:03:40

Amgen Inc.Reconciliation of GAAP EPS Guidance to Non-GAAP EPS Guidance for the Year Ending December 31, 2025(Unaudited)       G...

amgen-raises-fy2025-adj-eps-guidance-from-2020-2130-to-2060-2140-vs-2103-est
Amgen Raises FY2025 Adj EPS Guidance from ...
11/04/2025 21:03:17

Amgen (NASDAQ:AMGN) raises FY2025 Adj EPS guidance from $20.20-$21.30 to $20.60-$21.40 vs $21.03 analyst estimate..

amgen-q3-adj-eps-564-beats-501-estimate-sales-9557b-beat-8967b-estimate
Amgen Q3 Adj. EPS $5.64 Beats $5.01 Estima...
11/04/2025 21:02:20

Amgen (NASDAQ:AMGN) reported quarterly earnings of $5.64 per share which beat the analyst consensus estimate of $5.01 by 12.49 ...

palantir-weighs-on-wall-street-bitcoin-slumps-5-whats-moving-markets-tuesday
Palantir Weighs On Wall Street, Bitcoin Sl...
11/04/2025 18:22:32

Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, o...

earnings-scheduled-for-november-4-2025
Earnings Scheduled For November 4, 2025
11/04/2025 11:12:08

a-look-into-amgen-incs-price-over-earnings
A Look Into Amgen Inc's Price Over Earnings
10/31/2025 14:01:34

amgen-to-present-new-data-from-cardiovascular-portfolio-including-late-breaking-results-from-phase-3-vesalius-cv-clinical-trial-of-repatha-at-ahass-2025
Amgen To Present New Data From Cardiovascu...
10/31/2025 13:03:39

Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never ...

marjorie-taylor-greene-buys-netflix-stock-after-downbeat-q3-earnings-expands-big-tech-bet
Marjorie Taylor Greene Buys Netflix Stock ...
10/31/2025 07:08:12

MTG "buys the dip" on Netflix (NFLX) stock after a bad Q3 report. See all 14 of her new purchases, including MSFT and A...

Core News & Articles
Agilent Technologies Appoints Amgen Execut...
10/27/2025 20:21:17

Agilent Technologies Inc. (NYSE: A) today announced the appointment of Adam S. Elinoff as chief financial officer, effective No...

what-does-the-market-think-about-amgen-inc
What Does the Market Think About Amgen Inc?
10/27/2025 20:00:47

biogens-immunology-pipeline-has-long-term-potential-analyst
Biogen's Immunology Pipeline Has Long-Term...
10/24/2025 16:47:04

Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across mul...

Core News & Articles
Amgen Announces FDA Approval Of TEZSPIRE F...
10/17/2025 20:02:05

Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION